At a glance
ClinicalIndex Comparison Record- ✓English-speaking
- ✓African American ethnicity
- ✓Type 2 diabetes per American Diabetes Association criteria
- ✓Receiving care at Grady Hospital
- ✕Severely depressed (HAM-D ≥34)
- ✕Bipolar disorder, schizophrenia, psychotic disorder, OCD, or cognitive/developmental disorder (DSM-IV criteria)
- ✕Active suicide risk or serious suicide attempt in past year
- ✕Substance abuse or dependence (excluding nicotine) in past 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Depression-Diabetes Mechanisms: Urban African Americans
In Brief
A Phase 4 clinical trial evaluating Beating the Blues, Escitalopram, and 1 other intervention for Diabetes and Depression. Completed, enrolled 20 participants across 1 site.
Detailed Summary
African-Americans suffer from increased prevalence of both type 2 diabetes and diabetes complications, reflecting a combination of psychobehavioral factors as well as metabolic dysfunction. In this process, depression may contribute to both the genesis of type 2 diabetes (through impact on neurohormonal activation, inflammatory mediators, and insulin resistance), and difficulties in management (through decreased adherence to diet plans, medication, and scheduled appointments). The preliminary data from the Grady Diabetes Clinic indicates that depression may be common in African-Americans with diabetes, that depression is a factor in non-adherence, and that non-adherence leads to poor glycemic control - a direct cause of diabetes complications. What is not known is: how treatment of depression could lead to both neurohormonal and psychobiological improvement, with improved patient adherence and glycemic control.
Study Details
Timeline
Interventions
Beating the Blues is a computerized cognitive behavioral therapy.
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
A sugar pill taken as one to two tablets daily for 6 months.